Receptor Tyrosine Kinases: Translocation Partners in Hematopoietic Disorders.

Receptor tyrosine kinases (RTKs) activate various signaling pathways and regulate cellular proliferation, survival, migration, and angiogenesis. Malignant neoplasms often circumvent or subjugate these pathways by promoting RTK overactivation through mutation or chromosomal translocation. RTK translocations create a fusion protein containing a dimerizing partner fused to an RTK kinase domain, resulting in constitutive kinase domain activation, altered RTK cellular localization, upregulation of downstream signaling, and novel pathway activation. While RTK translocations in hematological malignancies are relatively rare, clinical evidence suggests that patients with these genetic abnormalities benefit from RTK-targeted inhibitors. Here, we present a timely review of an exciting field by examining RTK chromosomal translocations in hematological cancers, such as Anaplastic Lymphoma Kinase (ALK), Fibroblast Growth Factor Receptor (FGFR), Platelet-Derived Growth Factor Receptor (PDGFR), REarranged during Transfection (RET), Colony Stimulating Factor 1 Receptor (CSF1R), and Neurotrophic Tyrosine Kinase Receptor Type 3 (NTRK3) fusions, and discuss current therapeutic options.

[1]  J. Griffin,et al.  Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease , 2002, Oncogene.

[2]  J. Demoulin,et al.  New insights into the mechanisms of hematopoietic cell transformation by activated receptor tyrosine kinases. , 2010, Blood.

[3]  M. Eguchi,et al.  CLTC‐ALK fusion as a primary event in congenital blastic plasmacytoid dendritic cell neoplasm , 2014, Genes, chromosomes & cancer.

[4]  I. Lax,et al.  Heparin is an activating ligand of the orphan receptor tyrosine kinase ALK , 2015, Science Signaling.

[5]  J. Cools,et al.  The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11) , 2010, Haematologica.

[6]  Dynamics of double strand breaks and chromosomal translocations , 2014, Molecular Cancer.

[7]  J. Partanen,et al.  Fibroblast Growth Factor Receptor-1 Expression Is Required for Hematopoietic but not Endothelial Cell Development , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[8]  J. Delabie,et al.  ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions , 2010, Haematologica.

[9]  P. Marynen,et al.  Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large‐cell lymphoma and inflammatory myofibroblastic tumor , 2002, Genes, chromosomes & cancer.

[10]  J. Schlessinger,et al.  Contacts between membrane proximal regions of the PDGF receptor ectodomain are required for receptor activation but not for receptor dimerization , 2008, Proceedings of the National Academy of Sciences.

[11]  Annette S. Kim,et al.  Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204‐PDGFRB fusion in a patient with recurrent T‐ALL and an associated myeloproliferative neoplasm , 2012, Genes, chromosomes & cancer.

[12]  G. Webersinke,et al.  Functional characterization, localization, and inhibitor sensitivity of the TPR‐FGFR1 fusion in 8p11 myeloproliferative syndrome , 2016, Genes, chromosomes & cancer.

[13]  S. Mathew,et al.  BCR-PDGFRA fusion in a T lymphoblastic leukemia/lymphoma. , 2015, Cancer genetics.

[14]  Y. Ko,et al.  Identification of RANBP2–ALK fusion in ALK positive diffuse large B‐cell lymphoma , 2014, Hematological oncology.

[15]  H. Ohno,et al.  Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7. , 2015, Cancer genetics.

[16]  J. García,et al.  Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  R. Foà,et al.  A PDGFRB-positive acute myeloid malignancy with a new t(5;12)(q33;p13.3) involving the ERC1 gene , 2008, Leukemia.

[18]  Jianmin Yang,et al.  Fusion of platelet-derived growth factor receptor β to CEV14 gene in chronic myelomonocytic leukemia: A case report and review of the literature. , 2016, Oncology letters.

[19]  T. Kondo,et al.  FIP1L1 presence in FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes to the pathogenesis of distinct types of leukemia , 2014, Annals of Hematology.

[20]  G. Webersinke,et al.  Characterization of a newly identified ETV6-NTRK3 fusion transcript in acute myeloid leukemia , 2011, Diagnostic pathology.

[21]  William H. Bisson,et al.  Crizotinib-Resistant NPM-ALK Mutants Confer Differential Sensitivity to Unrelated Alk Inhibitors , 2012, Molecular Cancer Research.

[22]  M. Tomasson,et al.  Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage. , 2006, Blood.

[23]  J. Aster,et al.  Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581. , 2000, The Journal of clinical investigation.

[24]  L. Meltesen,et al.  Unusual childhood extramedullary hematologic malignancy with natural killer cell properties that contains tropomyosin 4--anaplastic lymphoma kinase gene fusion. , 2001, Blood.

[25]  Johanna Andrae,et al.  Role of platelet-derived growth factors in physiology and medicine. , 2008, Genes & development.

[26]  C. Heldin,et al.  Autoinhibition of the Platelet-derived Growth Factor β-Receptor Tyrosine Kinase by Its C-terminal Tail* , 2004, Journal of Biological Chemistry.

[27]  Paul D. Smith,et al.  Molecular Pathways Molecular Pathways : Fibroblast Growth Factor Signaling : A New Therapeutic Opportunity in Cancer , 2012 .

[28]  Andrew Chase,et al.  Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome , 2013, Haematologica.

[29]  M. Odero,et al.  NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. , 2004, Cancer research.

[30]  N. Schmitz,et al.  Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma , 2007, Leukemia.

[31]  S. Spurgeon,et al.  Chronic lymphocytic leukemia with a FGFR3 translocation: case report and literature review of an uncommon cytogenetic event. , 2014, Cancer genetics.

[32]  M. Ahn,et al.  Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer , 2015, PLoS genetics.

[33]  J. Tolar,et al.  Favorable outcome of allogeneic hematopoietic cell transplantation for 8p11 myeloproliferative syndrome associated with BCR‐FGFR1 gene fusion , 2012, Pediatric blood & cancer.

[34]  C. Haferlach,et al.  Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. , 2007, Haematologica.

[35]  Pengyuan Liu,et al.  Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer , 2014, Proceedings of the National Academy of Sciences.

[36]  C. Betsholtz,et al.  Basis of hematopoietic defects in platelet-derived growth factor (PDGF)-B and PDGF beta-receptor null mice. , 2001, Blood.

[37]  K. Ross,et al.  Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma , 2014, Oncotarget.

[38]  S. Pileri,et al.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation , 2014, Leukemia.

[39]  S. Pileri,et al.  Anaplastic lymphoma kinase in human cancer. , 2011, Journal of molecular endocrinology.

[40]  M. Ohira,et al.  ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma , 2013, Scientific Reports.

[41]  R. Herbrecht,et al.  A translocation t(2;8)(q12;p11) fuses FGFR1 to a novel partner gene, RANBP2/NUP358, in a myeloproliferative/myelodysplastic neoplasm , 2013, Leukemia.

[42]  L. Medeiros,et al.  8p11 myeloproliferative syndrome: a review. , 2010, Human pathology.

[43]  Ty C. Voss,et al.  DNA damage defines sites of recurrent chromosomal translocations in B lymphocytes , 2012, Nature.

[44]  D. Hume,et al.  The transcriptional regulation of the Colony-Stimulating Factor 1 Receptor (csf1r) gene during hematopoiesis. , 2008, Frontiers in bioscience : a journal and virtual library.

[45]  S. Paolini,et al.  FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features , 2016, American journal of hematology.

[46]  J. Demoulin,et al.  Critical Role of the Platelet-derived Growth Factor Receptor (PDGFR) β Transmembrane Domain in the TEL-PDGFRβ Cytosolic Oncoprotein* , 2010, The Journal of Biological Chemistry.

[47]  F. Grand,et al.  Identification of a novel imatinib responsive KIF5B-PDGFRA fusion gene following screening for PDGFRA overexpression in patients with hypereosinophilia , 2006, Leukemia.

[48]  R. Lai,et al.  Silibinin suppresses NPM-ALK, potently induces apoptosis and enhances chemosensitivity in ALK-positive anaplastic large cell lymphoma , 2015, Leukemia & lymphoma.

[49]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[50]  T. Matsui,et al.  A novel FOXP1-PDGFRA fusion gene in myeloproliferative neoplasm with eosinophilia. , 2015, Cancer genetics.

[51]  M. Werner,et al.  Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas , 2000, Leukemia.

[52]  R. Palmer,et al.  FAM150A and FAM150B are activating ligands for anaplastic lymphoma kinase , 2015, eLife.

[53]  A. Reiter,et al.  Two novel imatinib‐responsive PDGFRA fusion genes in chronic eosinophilic leukaemia , 2007, British journal of haematology.

[54]  J. Kutok,et al.  H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22). , 2001, Blood.

[55]  T. Taki,et al.  The leucine twenty homeobox (LEUTX) gene, which lacks a histone acetyltransferase domain, is fused to KAT6A in therapy‐related acute myeloid leukemia with t(8;19)(p11;q13) , 2014, Genes, chromosomes & cancer.

[56]  T. Fioretos,et al.  RNA-seq identifies clinically relevant fusion genes in leukemia including a novel MEF2D/CSF1R fusion responsive to imatinib , 2014, Leukemia.

[57]  Vassilis Roukos,et al.  The origins of ALK translocations. , 2015, Frontiers in bioscience.

[58]  E. Campo,et al.  Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma. , 2004, Human Pathology.

[59]  S. Constantinescu,et al.  Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK , 2011, Haematologica.

[60]  S. Morris,et al.  Detection of a TRAF1-ALK fusion in an anaplastic large cell lymphoma patient with chemotherapy and ALK inhibitor-resistant disease , 2015, BMC Research Notes.

[61]  C. Gambacorti-Passerini,et al.  Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma , 2014, Molecular Cancer Research.

[62]  S. Romana,et al.  LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome , 2009, Leukemia.

[63]  F. Locatelli,et al.  HCMOGT-1 is a novel fusion partner to PDGFRB in juvenile myelomonocytic leukemia with t(5;17)(q33;p11.2). , 2004, Cancer research.

[64]  Arthur Weiss,et al.  Switching Signals On or Off by Receptor Dimerization , 1998, Cell.

[65]  U. Germing,et al.  Fusion of H4/D10S170 to PDGFRβ in a patient with chronic myelomonocytic leukemia and long-term responsiveness to imatinib , 2007, Annals of Hematology.

[66]  Sungjoon Kim,et al.  Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 , 2013, Journal of medicinal chemistry.

[67]  Ricardo C T Aguiar,et al.  Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. , 2003, Blood.

[68]  M. K. Magnússon,et al.  Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukemia. , 2001, Blood.

[69]  L. Hawthorn,et al.  Induction of the plasminogen activator inhibitor-2 in cells expressing the ZNF198/FGFR1 fusion kinase that is involved in atypical myeloproliferative disease. , 2006, Blood.

[70]  W. Klapper,et al.  Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas , 2011, PloS one.

[71]  Rachel G Liao,et al.  Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors , 2014, Proceedings of the National Academy of Sciences.

[72]  E. Campo,et al.  Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells , 2004, Oncogene.

[73]  T. Misteli,et al.  Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma , 2009, Proceedings of the National Academy of Sciences.

[74]  D. Gilliland,et al.  Transforming Properties of the Huntingtin Interacting Protein 1/ Platelet-derived Growth Factor β Receptor Fusion Protein* , 1999, The Journal of Biological Chemistry.

[75]  J. Cayuela,et al.  Novel fusion between the breakpoint cluster region and platelet‐derived growth factor receptor‐alpha genes in a patient with chronic myeloid leukemia‐like neoplasm: undetectable residual disease after imatinib therapy , 2015, European journal of haematology.

[76]  N. Gray,et al.  The kinase ALK stimulates the kinase ERK5 to promote the expression of the oncogene MYCN in neuroblastoma , 2014, Science Signaling.

[77]  J. Zehnder,et al.  Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia , 2016, Leukemia.

[78]  C. Visco,et al.  STAT3 Pathway Is Activated in ALK-positive Large B-cell Lymphoma Carrying SQSTM1-ALK Rearrangement and Provides a Possible Therapeutic Target , 2013, The American journal of surgical pathology.

[79]  H. Ohno,et al.  Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)–anaplastic lymphoma kinase (ALK) acute myeloid leukemia , 2014, Leukemia.

[80]  N. Cross,et al.  Recurrent CEP85L–PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia , 2013, Leukemia & lymphoma.

[81]  S. Blackshaw,et al.  Characterization of the SUMO-Binding Activity of the Myeloproliferative and Mental Retardation (MYM)-Type Zinc Fingers in ZNF261 and ZNF198 , 2014, PloS one.

[82]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[83]  R. Palmer,et al.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology , 2013, Nature Reviews Cancer.

[84]  G. Delsol,et al.  TPM3-ALK expression induces changes in cytoskeleton organisation and confers higher metastatic capacities than other ALK fusion proteins. , 2007, European journal of cancer.

[85]  J. Cowell,et al.  Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease. , 2011, Blood.

[86]  J. Melo.  BCR-ABL gene variants. , 1997, Bailliere's clinical haematology.

[87]  C. Haferlach,et al.  Identification of a MYO18A‐PDGFRB fusion gene in an eosinophilia‐associated atypical myeloproliferative neoplasm with a t(5;17)(q33‐34;q11.2) , 2009, Genes, chromosomes & cancer.

[88]  G. Taylor,et al.  Regulation of the Src Homology 2-containing Inositol 5-Phosphatase SHIP1 in HIP1/PDGFβR-transformed Cells* , 2001, The Journal of Biological Chemistry.

[89]  J. Melo,et al.  The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins. , 2001, Blood.

[90]  N. Myeku,et al.  Dynamics of the Degradation of Ubiquitinated Proteins by Proteasomes and Autophagy , 2011, The Journal of Biological Chemistry.

[91]  N. Heisterkamp,et al.  Regulation of dendritic arborization by BCR Rac1 GTPase-activating protein, a substrate of PTPRT , 2012, Journal of Cell Science.

[92]  P. Dell’Era,et al.  Fibroblast Growth Factors and Their Receptors in Hematopoiesis and Hematological Tumors , 2002 .

[93]  C. Deswarte,et al.  RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation , 2012, Leukemia.

[94]  J. Demoulin,et al.  Platelet-derived growth factors and their receptors in normal and malignant hematopoiesis. , 2012, American journal of blood research.

[95]  Shinji Yamazaki,et al.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.

[96]  A. Jones,et al.  Oncogenic protein tyrosine kinases , 2004, Cellular and Molecular Life Sciences CMLS.

[97]  R. Gascoyne,et al.  Non‐muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma , 2003, Genes, chromosomes & cancer.

[98]  Jong-Yeon Shin,et al.  RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia. , 2014, Cancer genetics.

[99]  Tom Misteli,et al.  Spatial proximity of translocation-prone gene loci in human lymphomas , 2003, Nature Genetics.

[100]  Catherine Y. Marbehant,et al.  The tyrosine phosphatase SHP2 is required for cell transformation by the receptor tyrosine kinase mutants FIP1L1‐PDGFRα and PDGFRα D842V , 2014, Molecular oncology.

[101]  D. Gilliland,et al.  CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. , 2003, Blood.

[102]  R. V. van Etten,et al.  Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. , 2004, Cancer cell.

[103]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[104]  P. Marynen,et al.  Activation of FIP1L1-PDGFRα requires disruption of the juxtamembrane domain of PDGFRα and is FIP1L1-independent , 2006 .

[105]  I. Lax,et al.  Augmentor α and β (FAM150) are ligands of the receptor tyrosine kinases ALK and LTK: Hierarchy and specificity of ligand–receptor interactions , 2015, Proceedings of the National Academy of Sciences.

[106]  J. Cowell,et al.  Acute Progression of BCR-FGFR1 Induced Murine B-Lympho/Myeloproliferative Disorder Suggests Involvement of Lineages at the Pro-B Cell Stage , 2012, PloS one.

[107]  S. Demeyer,et al.  Generation of the Fip1l1–Pdgfra fusion gene using CRISPR/Cas genome editing , 2016, Leukemia.

[108]  M. BurkeRyan,et al.  The Role of PB1 Domain Proteins in Endothelial Cell Dysfunction and Disease. , 2015 .

[109]  D. DiMaio,et al.  Definition of an Inhibitory Juxtamembrane WW-like Domain in the Platelet-derived Growth Factor β Receptor* , 2002, The Journal of Biological Chemistry.

[110]  L. Knoops,et al.  ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB , 2012, Haematologica.

[111]  J. Jang,et al.  TRIP11-PDGFRB fusion in a patient with a therapy-related myeloid neoplasm with t(5;14)(q33;q32) after treatment for acute promyelocytic leukemia , 2014, Molecular Cytogenetics.

[112]  D. Fabbro,et al.  PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[113]  L. Michaux,et al.  The fusion proteins TEL-PDGFRβ and FIP1L1-PDGFRα escape ubiquitination and degradation , 2009, Haematologica.

[114]  S. Turner,et al.  Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency , 2016, Oncogene.

[115]  P. Marynen,et al.  A new NDE1/PDGFRB fusion transcript underlying chronic myelomonocytic leukaemia in Noonan Syndrome , 2007, Leukemia.

[116]  L. Medeiros,et al.  Hematolymphoid neoplasms associated with rearrangements of PDGFRA, PDGFRB, and FGFR1. , 2015, American journal of clinical pathology.

[117]  A. N. Meyer,et al.  Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. , 2015, Cytokine & growth factor reviews.

[118]  A. Chase,et al.  Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome. , 2007, Blood.

[119]  Deping Wang,et al.  Antitumor activity of S116836, a novel tyrosine kinase inhibitor, against imatinib-resistant FIP1L1-PDGFRα-expressing cells , 2014, Oncotarget.

[120]  T. Haferlach,et al.  Transient response to imatinib in a chronic eosinophilic leukemia associated with ins(9;4)(q33;q12q25) and a CDK5RAP2‐PDGFRA fusion gene , 2006, Genes, chromosomes & cancer.

[121]  T. Haferlach,et al.  Identification and functional characterization of imatinib‐sensitive DTD1‐PDGFRB and CCDC88C‐PDGFRB fusion genes in eosinophilia‐associated myeloid/lymphoid neoplasms , 2014, Genes, chromosomes & cancer.

[122]  E. Grande,et al.  Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment , 2011, Molecular Cancer Therapeutics.

[123]  Keith G. Thomas,et al.  Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways. , 2009, Experimental hematology.

[124]  B. Johansson,et al.  The impact of translocations and gene fusions on cancer causation , 2007, Nature Reviews Cancer.

[125]  G. Webersinke,et al.  p53-Binding Protein 1 Is Fused to the Platelet-Derived Growth Factor Receptor β in a Patient with a t(5;15)(q33;q22) and an Imatinib-Responsive Eosinophilic Myeloproliferative Disorder , 2004, Cancer Research.